<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36651622</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Common pathophysiology for ANXA11 disorders caused by aspartate 40 variants.</ArticleTitle><Pagination><StartPage>408</StartPage><EndPage>425</EndPage><MedlinePgn>408-425</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51731</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Mutations in ANXA11 cause amyotrophic lateral sclerosis (ALS) and have recently been identified as a cause of multisystem proteinopathy and adult-onset muscular dystrophy. These conditions are adult-onset diseases and result from the substitution of Aspartate 40 (Asp40) for an apolar residue in the intrinsically disordered domain (IDD) of ANXA11. Some ALS-related variants are known to affect ANXA11 IDD; however, the mechanism by which the myopathy occurs is unknown.</AbstractText><AbstractText Label="METHODS">Genetic analysis was performed using WES-trio. For the study of variant pathogenicity, we used recombinant proteins, muscle biopsy, and fibroblasts.</AbstractText><AbstractText Label="RESULTS">Here we describe an individual with severe and rapidly progressive childhood-onset oculopharyngeal muscular dystrophy who carries a new ANXA11 variant at position Asp40 (p.Asp40Ile; c.118_119delGAinsAT). p.Asp40Ile is predicted to enhance the aggregation propensity of ANXA11 to a greater extent than other changes affecting this residue. In vitro studies using recombinant ANXA11<sup>p.Asp40Ile</sup> showed abnormal phase separation and confirmed this variant is more aggregation-prone than the ALS-associated variant ANXA11<sup>p.Asp40Gly</sup> . The study of the patient's fibroblasts revealed defects in stress granules dynamics and clearance, and muscle histopathology showed a myopathic pattern with ANXA11 protein aggregates. Super-resolution imaging showed aggregates expressed as pearl strips or large complex structures in the sarcoplasm, and as layered subsarcolemmal chains probably reflecting ANXA11 multifunctionality.</AbstractText><AbstractText Label="INTERPRETATION">We demonstrate common pathophysiology for disorders associated with ANXA11 Asp40 allelic variants. Clinical phenotypes may result from different deleterious impacts of variants upon ANXA11 stability against aggregation, and differential muscle or motor neuron dysfunction expressed as a temporal and tissue-specific continuum.</AbstractText><CopyrightInformation>&#xa9; 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Natera-de Benito</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neuromuscular Unit, Department of Neurology, Hospital Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Applied Research in Neuromuscular Diseases, Institut de Recerca Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Olival</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics and Molecular Medicine - IPER, Institut de Recerca Sant Joan de D&#xe9;u, 08950, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Cabau</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, 08029, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jou</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Applied Research in Neuromuscular Diseases, Institut de Recerca Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Hospital Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roldan</LastName><ForeName>M&#xf2;nica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Confocal Microscopy and Cellular Imaging Unit, Institut de Recerca Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Developmental Medicine - IPER, Hospital Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Codina</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Applied Research in Neuromuscular Diseases, Institut de Recerca Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Exp&#xf3;sito-Escudero</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neuromuscular Unit, Department of Neurology, Hospital Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Applied Research in Neuromuscular Diseases, Institut de Recerca Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batlle</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics and Molecular Medicine - IPER, Institut de Recerca Sant Joan de D&#xe9;u, 08950, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carrera-Garc&#xed;a</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neuromuscular Unit, Department of Neurology, Hospital Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Applied Research in Neuromuscular Diseases, Institut de Recerca Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortez</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neuromuscular Unit, Department of Neurology, Hospital Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Applied Research in Neuromuscular Diseases, Institut de Recerca Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Research Network on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvatella</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, 08029, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ICREA, Barcelona, 08010, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Palau</LastName><ForeName>Francesc</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratory of Neurogenetics and Molecular Medicine - IPER, Institut de Recerca Sant Joan de D&#xe9;u, 08950, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Developmental Medicine - IPER, Hospital Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Research Network on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatrics, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, 08007, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ERN ITHACA, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nascimento</LastName><ForeName>Andr&#xe9;s</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neuromuscular Unit, Department of Neurology, Hospital Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Applied Research in Neuromuscular Diseases, Institut de Recerca Sant Joan de D&#xe9;u, Barcelona, 08950, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Research Network on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hoenicka</LastName><ForeName>Janet</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-6790-6988</Identifier><AffiliationInfo><Affiliation>Laboratory of Neurogenetics and Molecular Medicine - IPER, Institut de Recerca Sant Joan de D&#xe9;u, 08950, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Research Network on Rare Diseases (CIBERER), ISCIII, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009135" MajorTopicYN="Y">Muscular Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Xavier Salvatella is a founder and board member of Nuage Therapeutics. The other authors report no disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>7</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36651622</ArticleId><ArticleId IdType="pmc">PMC10014011</ArticleId><ArticleId IdType="doi">10.1002/acn3.51731</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liemann S, Huber R. Three&#x2010;dimensional structure of annexins. Cell Mol Life Sci. 1997;53:516&#x2010;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">9230929</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss SE, Morgan RO. The annexins. Genome Biol. 2004;5:219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC395778</ArticleId><ArticleId IdType="pubmed">15059252</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol. 2005;6:449&#x2010;461.</Citation><ArticleIdList><ArticleId IdType="pubmed">15928709</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Guo C, Liu S, et&#xa0;al. Annexin A11 in disease. Clin Chim Acta. 2014;431:164&#x2010;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">24508622</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao YC, Fernandopulle MS, Wang G, et&#xa0;al. RNA granules hitchhike on lysosomes for long&#x2010;distance transport, using annexin A11 as a molecular tether. Cell. 2019;179:147&#x2010;164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6890474</ArticleId><ArticleId IdType="pubmed">31539493</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahm M, Lim SM, Kim YE, et&#xa0;al. ANXA11 mutations in ALS cause dysregulation of calcium homeostasis and stress granule dynamics. Sci Transl Med. 2020;12:eaax3993.</Citation><ArticleIdList><ArticleId IdType="pubmed">33087501</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Gu J, Sun Q. Aberrant stress granule dynamics and aggrephagy in ALS pathogenesis. Cell. 2021;10:2247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8468025</ArticleId><ArticleId IdType="pubmed">34571896</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, Topp SD, Fallini C, et&#xa0;al. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci Transl Med. 2017;9:eaad9157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6599403</ArticleId><ArticleId IdType="pubmed">28469040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Liu Q, Liu K, et&#xa0;al. ANXA11 mutations prevail in Chinese ALS patients with and without cognitive dementia. Neurol Genet. 2018;4:e237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5963931</ArticleId><ArticleId IdType="pubmed">29845112</ArticleId></ArticleIdList></Reference><Reference><Citation>Leoni TB, Gonz&#xe1;lez&#x2010;Salazar C, Rezende TJR, et&#xa0;al. A novel multisystem proteinopathy caused by a missense ANXA11 variant. Ann Neurol. 2021;90:239&#x2010;252.</Citation><ArticleIdList><ArticleId IdType="pubmed">34048612</ArticleId></ArticleIdList></Reference><Reference><Citation>Johari M, Papadimas G, Papadopoulos C, et&#xa0;al. Adult&#x2010;onset dominant muscular dystrophy in Greek families caused by annexin A11. Ann Clin Transl Neurol. 2022;9(10):1660&#x2010;1667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9539373</ArticleId><ArticleId IdType="pubmed">36134701</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts GDJ, Wymer J, Kovach MJ, et&#xa0;al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin&#x2010;containing protein. Nat Genet. 2004;36:377&#x2010;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034582</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Kim NC, Wang YD, et&#xa0;al. Mutations in prion&#x2010;like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495:467&#x2010;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucelli RC, Arhzaouy K, Pestronk A, et&#xa0;al. SQSTM1 splice site mutation in distal myopathy with rimmed vacuoles. Neurology. 2015;85:665&#x2010;674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4553032</ArticleId><ArticleId IdType="pubmed">26208961</ArticleId></ArticleIdList></Reference><Reference><Citation>Senderek J, Garvey SM, Krieger M, et&#xa0;al. Autosomal&#x2010;dominant distal myopathy associated with a recurrent missense mutation in the gene encoding the nuclear matrix protein, matrin 3. Am J Hum Genet. 2009;84:511&#x2010;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2667977</ArticleId><ArticleId IdType="pubmed">19344878</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Mohassel P, Donkervoort S, et&#xa0;al. hnRNPA2B1 cause early&#x2010;onset oculopharyngeal muscular dystrophy. medRxiv:2021200420082125494220212004200821254942. 2021.</Citation></Reference><Reference><Citation>Li H, Durbin R. Fast and accurate long&#x2010;read alignment with burrows&#x2010;wheeler transform. Bioinformatics. 2010;26:589&#x2010;595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828108</ArticleId><ArticleId IdType="pubmed">20080505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopanos C, Tsiolkas V, Kouris A, et&#xa0;al. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35:1978&#x2010;1980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6546127</ArticleId><ArticleId IdType="pubmed">30376034</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards S, Aziz N, Bale S, et&#xa0;al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405&#x2010;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544753</ArticleId><ArticleId IdType="pubmed">25741868</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep&#x2010;sequencing age. Nat Methods. 2014;11:361&#x2010;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">24681721</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res. 2012;40:W452&#x2010;W457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3394338</ArticleId><ArticleId IdType="pubmed">22689647</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics. 2015;31:2745&#x2010;2747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4528627</ArticleId><ArticleId IdType="pubmed">25851949</ArticleId></ArticleIdList></Reference><Reference><Citation>Adzhubei IA, Schmidt S, Peshkin L, et&#xa0;al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7:248&#x2010;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2855889</ArticleId><ArticleId IdType="pubmed">20354512</ArticleId></ArticleIdList></Reference><Reference><Citation>Shihab HA, Rogers MF, Gough J, et&#xa0;al. An integrative approach to predicting the functional effects of non&#x2010;coding and coding sequence variation. Bioinformatics. 2015;31:1536&#x2010;1543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4426838</ArticleId><ArticleId IdType="pubmed">25583119</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47:D886&#x2010;D894.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323892</ArticleId><ArticleId IdType="pubmed">30371827</ArticleId></ArticleIdList></Reference><Reference><Citation>Karczewski KJ, Francioli LC, Tiao G, et&#xa0;al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434&#x2010;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334197</ArticleId><ArticleId IdType="pubmed">32461654</ArticleId></ArticleIdList></Reference><Reference><Citation>Landrum MJ, Lee JM, Benson M, et&#xa0;al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46:D1062&#x2010;D1067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5753237</ArticleId><ArticleId IdType="pubmed">29165669</ArticleId></ArticleIdList></Reference><Reference><Citation>Pe&#xf1;a&#x2010;Chilet M, Rold&#xe1;n G, Perez&#x2010;Florido J, et&#xa0;al. CSVS, a crowdsourcing database of the Spanish population genetic variability. Nucleic Acids Res. 2021;49:D1130&#x2010;D1137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7778906</ArticleId><ArticleId IdType="pubmed">32990755</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubowitz V, Sewry C, Oldfors A. Muscle Biopsy: A Practical Approach. Elsevier; 2013.</Citation></Reference><Reference><Citation>Romero P, Obradovic Z, Li X, Garner EC, Brown CJ, Dunker AK. Sequence complexity of disordered protein. Proteins. 2001;42:38&#x2010;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">11093259</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;oz V, Serrano L. Elucidating the folding problem of helical peptides using empirical parameters. Nat Struct Biol. 1994;1:399&#x2010;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">7664054</ArticleId></ArticleIdList></Reference><Reference><Citation>Conchillo&#x2010;Sol&#xe9; O, de Groot NS, Avil&#xe9;s FX, Vendrell J, Daura X, Ventura S. AGGRESCAN: a server for the prediction and evaluation of &#x201c;hot spots&#x201d; of aggregation in polypeptides. BMC Bioinform. 2007;8:65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1828741</ArticleId><ArticleId IdType="pubmed">17324296</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberti S, Saha S, Woodruff JB, Franzmann TM, Wang J, Hyman AA. A user's guide for phase separation assays with purified proteins. J Mol Biol. 2018;430:4806&#x2010;4820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6215329</ArticleId><ArticleId IdType="pubmed">29944854</ArticleId></ArticleIdList></Reference><Reference><Citation>Larionov A, Krause A, Miller WR. A standard curve based method for relative real time PCR data processing. BMC Bioinform. 2005;6:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1274258</ArticleId><ArticleId IdType="pubmed">15780134</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Mohassel P, Donkervoort S, et&#xa0;al. Heterozygous frameshift variants in HNRNPA2B1 cause early&#x2010;onset oculopharyngeal muscular dystrophy. Nat Commun. 2022;13(1):2306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9050844</ArticleId><ArticleId IdType="pubmed">35484142</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher MWKJ, Davis LE, Bear DG. Intranuclear inclusions in oculopharyngeal muscular dystrophy contain poly(a) binding protein 2. Ann Neurol. 2000;48:812&#x2010;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">11079550</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D, Hatano M, Suzuki N. RNA binding proteins and the pathological cascade in ALS/FTD neurodegeneration. Sci Transl Med. 2017;9:eaah5436.</Citation><ArticleIdList><ArticleId IdType="pubmed">29118263</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidib&#xe9; H, Dubinski A, Vande VC. The multi&#x2010;functional RNA&#x2010;binding protein G3BP1 and its potential implication in neurodegenerative disease. J Neurochem. 2021;157:944&#x2010;962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8248322</ArticleId><ArticleId IdType="pubmed">33349931</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B, Zhang L, Dai T, et&#xa0;al. Liquid&#x2013;liquid phase separation in human health and diseases. Signal Transduct Target Ther. 2021;6:290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8326283</ArticleId><ArticleId IdType="pubmed">34334791</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Lee R, Lang B, Kruse K, et&#xa0;al. Intrinsically disordered segments affect protein half&#x2010;life in the cell and during evolution. Cell Rep. 2014;8(6):1832&#x2010;1844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4358326</ArticleId><ArticleId IdType="pubmed">25220455</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzano R, Toivonen JM, Moreno&#x2010;Martinez L, et&#xa0;al. What skeletal muscle has to say in amyotrophic lateral sclerosis: implications for therapy. Br J Pharmacol. 2021;178(6):1279&#x2010;1297.</Citation><ArticleIdList><ArticleId IdType="pubmed">32986860</ArticleId></ArticleIdList></Reference><Reference><Citation>Pikatza&#x2010;Menoio O, Elicegui A, Bengoetxea X, et&#xa0;al. The skeletal muscle emerges as a new disease target in amyotrophic lateral sclerosis. J Pers Med. 2021;11(7):671.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8307751</ArticleId><ArticleId IdType="pubmed">34357138</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>